advertisement
Abstract #18354 Published in IGR 3-3
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SMAmerican Journal of Ophthalmology 2001; 132: 472-484
PURPOSE: This study evaluated the safety and intraocular pressure (IOP)-lowering efficacy of two concentrations of travoprost (0.0015% and 0.004%) compared with latanoprost 0.005% and timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. METHODS: Eight hundred and one patients with open-angle glaucoma or ocular hypertension were randomly assigned to travoprost 0.0015%, travoprost 0.004%, latanoprost 0.005%, or timolol 0.5%. The efficacy and safety of travoprost (0.0015% and 0.004%) daily was compared with latanoprost daily and timolol twice daily for a period of 12 months. RESULTS: Travoprost was equal or superior to latanoprost and superior to timolol with mean IOP over visits and time of day ranging from 17.9-19.1 mmHg (travoprost 0.0015%), 17.7-19.1 mmHg (travoprost 0.004%), 18.5-19.2 mmHg (latanoprost), and 19.4-20.3 mmHg (timolol). For all visits pooled, the mean IOP at 4 p.m. for travoprost was 0.7 mmHg (0.0015%, p = 0.0502) and 0.8 mmHg (0.004%, p = 0.0191) lower than for latanoprost. Travoprost 0.004% was more effective than latanoprost and timolol in reducing IOP in black patients by up to 2.4 mmHg (versus latanoprost) and 4.6 mmHg (versus timolol). Based on a criterion of 30% or greater IOP reduction from diurnal baseline or IOP 17 mmHg or less, travoprost 0.0015% and 0.004% had an overall response to treatment of 49.3% and 54.7%, respectively, compared with 49.6% for latanoprost and 39.0% for timolol. Iris pigmentation change was observed in ten of 201 of patients (5.0%) receiving travoprost 0.0015%, six of 196 of patients (3.1%) receiving travoprost 0.004%, ten of 194 of patients (5.2%) receiving latanoprost, and in none of the patients receiving timolol (0 of 196). The average ocular hyperemia score was less than 1 on a scale of 0 to 3, indicating that, on average, patients experienced between none/trace and mild for all treatment groups. There were no serious, unexpected, related adverse events reported for any therapy. CONCLUSIONS: Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist, is equal or superior to latanoprost and superior to timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. In addition, travoprost 0.004% is significantly better than either latanoprost or timolol in lowering IOP in black patients. Travoprost is safe and generally well tolerated in the studied patient population.
Dr P.A. Netland, Department of Ophthalmology, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA. pnetland@mail.eye.utmem.edu
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
